Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharma Q3 revenue rises to $37.7 million, net loss narrows to $35.6 million

Positive Impact 3 of 5 earnings Written later

ARS Pharmaceuticals reported third-quarter 2026 total revenue of $37.7 million, up from $32.5 million a year earlier, and a net loss of $35.6 million, or $(0.36) per share, compared with a net loss of $51.2 million, or $(0.52) per share, in the prior-year quarter. The company reaffirmed its expectation to reach cash flow breakeven by the end of 2027 and appointed a new Chief Medical Officer and Chief Legal Officer.

Key points

  • Q3 2026 total revenue was $37.7 million, including U.S. net product revenue for neffy of $33.4 million, versus $32.5 million in Q3 2025.
  • Q3 2026 SG&A expenses were $43.5 million, compared with $74.8 million in Q3 2025, and R&D expenses were $18.3 million, including a one-time $12.5 million license payment.
  • Cash, cash equivalents and short-term investments were $138.4 million as of September 30, 2026; the company continues to expect cash flow breakeven by the end of 2027.

The filing

CompanyARS Pharmaceuticals, Inc. (SPRY)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:04 PM ET
Accession number0001193125-26-449748

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.